Skip to content
BoardCited

Adulterated and misbranded drugs, recalls, expiration, counterfeits, EUAs, importation, DSCSA

3 free Uniform MPJE practice questions on this topic, with the answer, a reason for every option and the source. The full bank has 85 questions here.

Question 1Single answer

FDA inspects a drug manufacturer and finds that its manufacturing controls do not conform to current good manufacturing practice (cGMP), although every lot of the finished tablets passed release testing. Under the FD&C Act, the tablets are:

  1. Amisbranded, because the labeling implies cGMP compliance
  2. Badulterated, even though the finished lots meet their specifications
  3. Cnot in violation, because the finished lots meet their specifications
Show answer and sources

Answer: B. adulterated, even though the finished lots meet their specifications

Failure of manufacturing methods, facilities, or controls to conform to cGMP makes a drug adulterated (21 U.S.C. 351(a)(2)(B)), even if the finished product tests within specification.

  • A. Incorrect: cGMP failure is an adulteration ground, not a misbranding ground.
  • B. Correct: a drug made with methods, facilities, or controls that do not conform to cGMP is adulterated under 21 U.S.C. 351(a)(2)(B), regardless of final test results.
  • C. Incorrect: passing release testing does not cure a cGMP failure; nonconformity alone makes the drug adulterated.
  1. [1] 21 U.S.C. §351 — Adulterated drugs . 21 U.S.C. 351(a)(2)(B)
Question 2Single answer

A hospital pharmacy sends a sample of a USP-recognized injection for testing. The compendial assay shows the product contains 85% of the strength required by the USP standard, and its label does not mention any difference. Under the FD&C Act, the injection is:

  1. Aadulterated, because its strength differs from the compendial standard
  2. Bacceptable, because only a strength above the compendial standard is a violation
  3. Cacceptable, because the lot has not yet reached its expiration date
Show answer and sources

Answer: A. adulterated, because its strength differs from the compendial standard

A drug recognized in an official compendium is adulterated if its strength differs from, or its quality or purity falls below, the compendial standard (21 U.S.C. 351(b)).

  • A. Correct: a compendial drug whose strength differs from the official standard, without a plain label statement of the difference, is adulterated under 21 U.S.C. 351(b).
  • B. Incorrect: 351(b) covers any difference in strength, whether above or below the standard.
  • C. Incorrect: an unexpired product is still adulterated if it fails the compendial strength standard.
  1. [1] 21 U.S.C. §351 — Adulterated drugs . 21 U.S.C. 351(b)
Question 3Single answer

FDA investigators arrive at a pharmacy to inspect its compounding area. The owner refuses to let them enter. Under the FD&C Act, the drugs held at the pharmacy are:

  1. Adeemed adulterated because the owner refused the inspection
  2. Bdeemed misbranded because the owner refused the inspection
  3. Cunaffected, because refusal results only in a fine against the owner
Show answer and sources

Answer: A. deemed adulterated because the owner refused the inspection

A drug is adulterated if it was held in an establishment whose owner, operator, or agent delays, denies, or limits an FDA inspection or refuses entry (21 U.S.C. 351(j)); refusal is also a prohibited act under 331(f).

  • A. Correct: drugs held in an establishment whose owner, operator, or agent delays, denies, limits, or refuses an FDA inspection are deemed adulterated (21 U.S.C. 351(j)).
  • B. Incorrect: the statute places refusal of inspection under adulteration, not misbranding.
  • C. Incorrect: refusal is also a prohibited act (331(f)), and 351(j) deems the drugs adulterated.
  1. [1] 21 U.S.C. §351 — Adulterated drugs . 21 U.S.C. 351(j)
  2. [2] 21 U.S.C. §331 — FDCA prohibited acts . 21 U.S.C. 331(f)

Practise all 85 questions on this topic

Tutor mode, timed blocks and progress tracking.

Start free